Johnson & Johnson Income Taxes 2010-2024 | JNJ

Johnson & Johnson annual/quarterly income taxes history and growth rate from 2010 to 2024. Income taxes can be defined as the total amount of income tax expense for the given period.
  • Johnson & Johnson income taxes for the quarter ending March 31, 2024 were $1.086B, a 262.33% decline year-over-year.
  • Johnson & Johnson income taxes for the twelve months ending March 31, 2024 were $3.491B, a 117.24% increase year-over-year.
  • Johnson & Johnson annual income taxes for 2023 were $1.736B, a 41.92% decline from 2022.
  • Johnson & Johnson annual income taxes for 2022 were $2.989B, a 117.07% increase from 2021.
  • Johnson & Johnson annual income taxes for 2021 were $1.377B, a 22.77% decline from 2020.
Johnson & Johnson Annual Income Taxes
(Millions of US $)
2023 $1,736
2022 $2,989
2021 $1,377
2020 $1,783
2019 $2,209
2018 $2,702
2017 $16,373
2016 $3,263
2015 $3,787
2014 $4,240
2013 $1,640
2012 $3,261
2011 $2,689
2010 $3,613
2009 $3,489
Johnson & Johnson Quarterly Income Taxes
(Millions of US $)
2024-03-31 $1,086
2023-12-31 $-121
2023-09-30 $908
2023-06-30 $1,618
2023-03-31 $-669
2022-12-31 $388
2022-09-30 $862
2022-06-30 $1,026
2022-03-31 $713
2021-12-31 $-421
2021-09-30 $182
2021-06-30 $384
2021-03-31 $1,232
2020-12-31 $-91
2020-09-30 $847
2020-06-30 $314
2020-03-31 $713
2019-12-31 $208
2019-09-30 $-106
2019-06-30 $1,434
2019-03-31 $673
2018-12-31 $80
2018-09-30 $489
2018-06-30 $1,019
2018-03-31 $1,114
2017-12-31 $13,273
2017-09-30 $1,026
2017-06-30 $921
2017-03-31 $1,153
2016-12-31 $510
2016-09-30 $1,009
2016-06-30 $907
2016-03-31 $837
2015-12-31 $543
2015-09-30 $764
2015-06-30 $1,225
2015-03-31 $1,255
2014-12-31 $182
2014-09-30 $2,061
2014-06-30 $1,300
2014-03-31 $697
2013-12-31 $-769
2013-09-30 $685
2013-06-30 $960
2013-03-31 $764
2012-12-31 $533
2012-09-30 $966
2012-06-30 $627
2012-03-31 $1,135
2011-12-31 $100
2011-09-30 $909
2011-06-30 $646
2011-03-31 $1,034
2010-12-31 $286
2010-09-30 $802
2010-06-30 $771
2010-03-31 $1,754
2009-12-31 $398
2009-09-30 $900
2009-06-30 $1,055
2009-03-31 $1,136
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $353.804B $85.159B
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $688.746B 114.69
Novo Nordisk (NVO) Denmark $564.487B 46.50
Merck (MRK) United States $331.117B 60.24
AbbVie (ABBV) United States $296.212B 15.06
AstraZeneca (AZN) United Kingdom $232.626B 20.22
Novartis AG (NVS) Switzerland $202.479B 14.36
Pfizer (PFE) United States $143.036B 13.80
Sanofi (SNY) $124.861B 11.78
Innoviva (INVA) United States $0.948B 6.69